Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Gains from Sales and Divestitures (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Gains from Sales and Divestitures data on record, last reported at $273546.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 1109.52% year-over-year to $273546.0; the TTM value through Sep 2025 reached $273546.0, up 1109.52%, while the annual FY2024 figure was $30002.0, 4.49% down from the prior year.
  • Gains from Sales and Divestitures reached $273546.0 in Q3 2025 per RANI's latest filing, up from $215745.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $273546.0 in Q3 2025 and bottomed at $15058.0 in Q3 2021.
  • Average Gains from Sales and Divestitures over 5 years is $112028.7, with a median of $30706.5 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 1677.46% in 2022, then plummeted 88.26% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $21800.0 in 2021, then soared by 1127.75% to $267650.0 in 2022, then tumbled by 88.26% to $31411.0 in 2023, then decreased by 4.49% to $30002.0 in 2024, then surged by 811.76% to $273546.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $273546.0 in Q3 2025, $215745.0 in Q2 2025, and $156886.0 in Q1 2025.